Clinical Trial Update: MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for MiRisten to treat relapsed or refractory acute myeloid leukemia. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• MiRisten

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Status: RECRUITING